Available online 5 April 2023

This paper reviews 30 years of developments in the area of low-grade gliomas. This includes the changes in diagnostics with the incorporation of 1p/19q and IDH mutations in the diagnostic classifier, the improved surgical techniques, improved delivery of radiotherapy and chemotherapy. More recently, the better understanding of the altered cellular processes has lead to the development of novel drugs that may alter completely alter the management of patients early in the course of their disease.

Astrocytoma IDH mutant

Oligodendroglioma

PCV

Temozolomide

History

© 2023 The Author(s). Published by Elsevier Masson SAS.